Tombowl
12-14-2022, 02:05 AM
The ongoing phase II BYLieve trial is evaluating second line alpelisib in combination with either fulvestrant or letrozole in PIK3CA mutant patients who had previously received a CDK4 6 inhibitor tamoxifen gynecomastia before and after ([Only registered and activated users can see links])